The estate of an inmate who died in the custody of an Horry County detention center has filed a lawsuit claiming negligence ...
SEATTLE--(BUSINESS WIRE)--Proniras Corporation (“Proniras”), a clinical-stage biotechnology company developing novel small-molecule therapeutics for the treatment of substance use and specialty ...
Myrtle Beach Sun News on MSN
Inmate died after negligent medical care in Horry County jail, lawsuit claims
Over the next few days, after being jailed, Carroll exhibited symptoms of "severe opiate withdrawal," the lawsuit says. He ...
Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...
As a pharmacist for HCMC and Hennepin emergency services, Holly Drone has seen a lot. But when Drone described the pain of opiate withdrawal on patients, she turned to her clients’ and co-workers’ ...
Sedation rapid opiate detox treatment is for motivated patients who want to live free of all opiates without substituting Suboxone or Methadone. Acute withdrawals are the main reason why such patients ...
Twenty-four percent of US adolescent treatment centers do not use a “lifesaving” medication. An article appeared today in the Journal of the American Medical Association titled “Treatments Used Among ...
A nursery in Arizona is caring for the youngest victims of the opioid crisis. Hushabye Nursery, in Phoenix, treats babies with neonatal abstinence syndrome, a withdrawal-like condition caused by ...
Share on Pinterest CBD derivatives showed promise in supplementing the opioid overdose drug naloxone. Micky Wiswedel/Stocksy United Researchers are studying how specific components of cannabidiol (CBD ...
Third-party research groups and organizations have validated a smartphone app called Reflex as a tool to help diagnose medical conditions like concussions and opiate withdrawal. Brightlamp CEO Kurtis ...
Sparian Biosciences Inc. has been awarded a $19.5 million, 5-year grant to fund development of SBS-226 from IND submission through phase I development. SBS-226 is a first-in-class dual μ-opioid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results